PROTALIX BIOTHERAPEUTICS, INC. (PLX)

[TechandBio]

Sanofi or Takeda might throw a curve ball and steal PLX from Chiesi before the approval dates CHMP EU in a few weeks.
Lots of M & A happens as early as Phase 2 PLX has three Phase 3 Trials completed + more data following up on those patients.
The key is on the switch over trial there was over 97%+ retention from patients who switched from Fabrazyme to PLX 102 wanted to stay on PLX drug less side effects and half the infusion times a month is a key factor. SNY might want to monopolize the Fabry space. Takeda can also come in and swoop 102 from Chiesi time will tell.

$PLX
$SNY
$TAK